PNPLA3-Associated Steatohepatitis: Toward a Gene-Based Classification of Fatty Liver Disease

 

 Permissions and Reprints

Abstract

Nonalcoholic fatty liver disease is one of the most common hepatic disorders worldwide. Given the high-calorie nutrition of children and adults, nonalcoholic fatty liver disease (NAFLD) is expected to become a major cause of cirrhosis and eventually liver transplantation. Familial clustering and ethnic differences indicate that genetic factors contribute to NAFLD. Recently, the common variant p.I148M of the enzyme adiponutrin (PNPLA3) has emerged as a major genetic determinant of hepatic steatosis and nonalcoholic steatohepatitis as well as its pathobiological sequelae fibrosis, cirrhosis, and hepatocellular cancer. PNPLA3 encodes a lipid droplet-associated, carbohydrate-regulated lipogenic and/or lipolytic enzyme. Homozygous carriers of the PNPLA3 variant are prone to develop cirrhosis in the absence of other risk factors such as alcohol or viral hepatitis. Here we review the plethora of studies that unraveled the association between PNPLA3 and NAFLD in children and adults, discuss its distinct effects on liver and metabolic traits, and introduce the term PNPLA3-associated steatohepatitis (PASH) as a novel gene-based liver disease. Given the prevalence of the risk allele in 40 to 50% of Europeans, the authors conclude that PNPLA3 should be considered in the diagnostic workup of fatty liver disease and that homozygous risk allele carriers might benefit from careful cancer surveillance.

• References

• 1 Lazo M, Hernaez R, Eberhardt MS , et al. Prevalence of nonalcoholic fatty liver disease in the United States: the third national health and nutrition examination survey, 1988–1994. Am J Epidemiol 2013; 178 (1) 38-45
  CrossrefPubMedGoogle Scholar
• 2 Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013; 58 (3) 593-608
  CrossrefPubMedGoogle Scholar
• 3 Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34 (3) 274-285
  CrossrefPubMedGoogle Scholar
• 4 Williams CD, Stengel J, Asike MI , et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140 (1) 124-131
  CrossrefPubMedGoogle Scholar
• 5 Chalasani N, Younossi Z, Lavine JE , et al; American Gastroenterological Association; American Association for the Study of Liver Diseases; American College of Gastroenterologyh. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142 (7) 1592-1609
  CrossrefPubMedGoogle Scholar
• 6 Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10 (6) 330-344
  CrossrefPubMedGoogle Scholar
• 7 Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012; 142 (4) 711-725 , e6
  CrossrefPubMedGoogle Scholar
• 8 Sanyal AJ, Brunt EM, Kleiner DE , et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011; 54 (1) 344-353
  CrossrefPubMedGoogle Scholar
• 9 Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53 (6) 1883-1894
  CrossrefPubMedGoogle Scholar
• 10 Zechner R, Zimmermann R, Eichmann TO , et al. FAT SIGNALS—lipases and lipolysis in lipid metabolism and signaling. Cell Metab 2012; 15 (3) 279-291
  CrossrefPubMedGoogle Scholar
• 11 Huang Y, He S, Li JZ , et al. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A 2010; 107 (17) 7892-7897
  CrossrefPubMedGoogle Scholar
• 12 Romeo S, Kozlitina J, Xing C , et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40 (12) 1461-1465
  CrossrefPubMedGoogle Scholar
• 13 Mohanty SR, Troy TN, Huo D, O'Brien BL, Jensen DM, Hart J. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol 2009; 50 (4) 797-804
  CrossrefPubMedGoogle Scholar
• 14 Weston SR, Leyden W, Murphy R , et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 2005; 41 (2) 372-379
  CrossrefPubMedGoogle Scholar
• 15 Browning JD, Szczepaniak LS, Dobbins R , et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40 (6) 1387-1395
  CrossrefPubMedGoogle Scholar
• 16 Yuan X, Waterworth D, Perry JR , et al. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet 2008; 83 (4) 520-528
  CrossrefPubMedGoogle Scholar
• 17 Chambers JC, Zhang W, Sehmi J , et al; Alcohol Genome-wide Association (AlcGen) Consortium; Diabetes Genetics Replication and Meta-analyses (DIAGRAM+) Study; Genetic Investigation of Anthropometric Traits (GIANT) Consortium; Global Lipids Genetics Consortium; Genetics of Liver Disease (GOLD) Consortium; International Consortium for Blood Pressure (ICBP-GWAS); Meta-analyses of Glucose and Insulin-Related Traits Consortium (MAGIC). Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet 2011; 43 (11) 1131-1138
  CrossrefPubMedGoogle Scholar
• 18 Kotronen A, Johansson LE, Johansson LM , et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 2009; 52 (6) 1056-1060
  CrossrefPubMedGoogle Scholar
• 19 Speliotes EK, Yerges-Armstrong LM, Wu J , et al; NASH CRN; GIANT Consortium; MAGIC Investigators; GOLD Consortium. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011; 7 (3) e1001324
  CrossrefPubMedGoogle Scholar
• 20 Sookoian S, Castaño GO, Burgueño AL, Gianotti TF, Rosselli MS, Pirola CJ. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res 2009; 50 (10) 2111-2116
  CrossrefPubMedGoogle Scholar
• 21 Valenti L, Al-Serri A, Daly AK , et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51 (4) 1209-1217
  CrossrefPubMedGoogle Scholar
• 22 Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ ; NASH CRN. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010; 52 (3) 894-903
  CrossrefPubMedGoogle Scholar
• 23 Anstee QM, Darlay R, Leathart J , et al. A candidate-gene approach to validation of genetic modifier association using a large cohort with histologically characterized non-alcoholic fatty liver disease. J Hepatol 2013; 55 (1) S46
  PubMedGoogle Scholar
• 24 Krawczyk M, Müllenbach R, Weber SN, Zimmer V, Lammert F. Genome-wide association studies and genetic risk assessment of liver diseases. Nat Rev Gastroenterol Hepatol 2010; 7 (12) 669-681
  CrossrefPubMedGoogle Scholar
• 25 Krawczyk M, Grünhage F, Zimmer V, Lammert F. Variant adiponutrin (PNPLA3) represents a common fibrosis risk gene: non-invasive elastography-based study in chronic liver disease. J Hepatol 2011; 55 (2) 299-306
  CrossrefPubMedGoogle Scholar
• 26 Kawaguchi T, Sumida Y, Umemura A , et al; Japan Study Group of Nonalcoholic Fatty Liver Disease; Takeshi Okanoue. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS ONE 2012; 7 (6) e38322
  CrossrefPubMedGoogle Scholar
• 27 Kitamoto T, Kitamoto A, Yoneda M , et al. Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Hum Genet 2013; 132 (7) 783-792
  CrossrefPubMedGoogle Scholar
• 28 Tian C, Stokowski RP, Kershenobich D, Ballinger DG, Hinds DA. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet 2010; 42 (1) 21-23
  CrossrefPubMedGoogle Scholar
• 29 Stickel F, Buch S, Lau K , et al. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in Caucasians. Hepatology 2011; 53 (1) 86-95
  CrossrefPubMedGoogle Scholar
• 30 Trépo E, Gustot T, Degré D , et al. Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. J Hepatol 2011; 55 (4) 906-912
  CrossrefPubMedGoogle Scholar
• 31 Müller T, Buch S, Berg T, Hampe J, Stickel F. Distinct, alcohol-modulated effects of PNPLA3 genotype on progression of chronic hepatitis C. J Hepatol 2011; 55 (3) 732-733
  CrossrefPubMedGoogle Scholar
• 32 Cai T, Dufour JF, Muellhaupt B , et al; Swiss Hepatitis C Cohort Study Group. Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis. J Hepatol 2011; 55 (3) 529-535
  CrossrefPubMedGoogle Scholar
• 33 Valenti L, Rumi M, Galmozzi E , et al. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 2011; 53 (3) 791-799
  CrossrefPubMedGoogle Scholar
• 34 Trépo E, Pradat P, Potthoff A , et al. Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology 2011; 54 (1) 60-69
  CrossrefPubMedGoogle Scholar
• 35 Zampino R, Coppola N, Cirillo G , et al. Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C. J Viral Hepat 2013; 20 (8) 517-523
  CrossrefPubMedGoogle Scholar
• 36 Vigano M, Valenti L, Lampertico P , et al. Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B. Hepatology 2013;
  PubMedGoogle Scholar
• 37 Trépo E, Guyot E, Ganne-Carrie N , et al. PNPLA3 (rs738409 C>G) is a common risk variant associated with hepatocellular carcinoma in alcoholic cirrhosis. Hepatology 2012; 55 (4) 1307-1308
  CrossrefPubMedGoogle Scholar
• 38 Burza MA, Pirazzi C, Maglio C , et al. PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals. Dig Liver Dis 2012; 44 (12) 1037-1041
  CrossrefPubMedGoogle Scholar
• 39 Hassan MM, Kaseb A, Etzel CJ , et al. Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction. Mol Carcinog 2013;
  PubMedGoogle Scholar
• 40 Nischalke HD, Berger C, Luda C , et al. The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. PLoS ONE 2011; 6 (11) e27087
  CrossrefPubMedGoogle Scholar
• 41 Takeuchi Y, Ikeda F, Moritou Y , et al. The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis. J Gastroenterol 2013; 48 (3) 405-412
  CrossrefPubMedGoogle Scholar
• 42 Liu YL, Patman G, Leathart J , et al. Carriage of PNPLA3 I148M is associated with an increases risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol 2013; 58 (1) S516
  PubMedGoogle Scholar
• 43 do O NT, Eurich D, Trautwein C, Neuhaus P, Neumann UP, Wasmuth HE. The common I148 M variant of PNPLA3 does not predict fibrosis progression after liver transplantation for hepatitis C. Hepatology 2011; 54 (4) 1483-1484
  CrossrefPubMedGoogle Scholar
• 44 Finkenstedt A, Auer C, Glodny B , et al. PNPLA3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis. Clin Gastroenterol Hepatol 2013; ; [Epub ahead of print]
  PubMedGoogle Scholar
• 45 Valenti L, Alisi A, Galmozzi E , et al. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 2010; 52 (4) 1274-1280
  CrossrefPubMedGoogle Scholar
• 46 Santoro N, Kursawe R, D'Adamo E , et al. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology 2010; 52 (4) 1281-1290
  CrossrefPubMedGoogle Scholar
• 47 Lin YC, Chang PF, Hu FC, Yang WS, Chang MH, Ni YH. A common variant in the PNPLA3 gene is a risk factor for non-alcoholic fatty liver disease in obese Taiwanese children. J Pediatr 2011; 158 (5) 740-744
  PubMedGoogle Scholar
• 48 Larrieta-Carrasco E, León-Mimila P, Villarreal-Molina T , et al. Association of the I148M/PNPLA3 variant with elevated alanine transaminase levels in normal-weight and overweight/obese Mexican children. Gene 2013; 520 (2) 185-188
  CrossrefPubMedGoogle Scholar
• 49 Krawczyk M, Maier IB, Liebe R, Lammert F, Bergheim I. The common adiponutrin (PNPLA3) variant is associated with subclinical liver injury already in young age: analysis of a cohort of paediatric patients. J Hepatol 2013; 58 (Suppl. 01) S559-S560
  PubMedGoogle Scholar
• 50 Marzuillo P, Grandone A, Perrone L, Miraglia Del Giudice E. Weight loss allows the dissection of the interaction between abdominal fat and PNPLA3 (adiponutrin) in the liver damage of obese children. J Hepatol 2013;
  PubMedGoogle Scholar
• 51 Romeo S, Sentinelli F, Cambuli VM , et al. The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. J Hepatol 2010; 53 (2) 335-338
  CrossrefPubMedGoogle Scholar
• 52 Palasciano G, Moschetta A, Palmieri VO, Grattagliano I, Iacobellis G, Portincasa P. Non-alcoholic fatty liver disease in the metabolic syndrome. Curr Pharm Des 2007; 13 (21) 2193-2198
  CrossrefPubMedGoogle Scholar
• 53 Krarup NT, Grarup N, Banasik K , et al. The PNPLA3 rs738409 G-allele associates with reduced fasting serum triglyceride and serum cholesterol in Danes with impaired glucose regulation. PLoS ONE 2012; 7 (7) e40376
  CrossrefPubMedGoogle Scholar
• 54 Krawczyk M, Grünhage F, Mahler M, Tirziu S, Acalovschi M, Lammert F. The common adiponutrin variant p.I148M does not confer gallstone risk but affects fasting glucose and triglyceride levels. J Physiol Pharmacol 2011; 62 (3) 369-375
  PubMedGoogle Scholar
• 55 Rembeck K, Maglio C, Lagging M , et al; NORDynamIC group. PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection. BMC Med Genet 2012; 13: 82
  CrossrefPubMedGoogle Scholar
• 56 Palmer CN, Maglio C, Pirazzi C , et al. Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant. PLoS ONE 2012; 7 (6) e39362
  CrossrefPubMedGoogle Scholar
• 57 Pirazzi C, Adiels M, Burza MA , et al. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol 2012; 57 (6) 1276-1282
  CrossrefPubMedGoogle Scholar
• 58 Kantartzis K, Peter A, Machicao F , et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 2009; 58 (11) 2616-2623
  CrossrefPubMedGoogle Scholar
• 59 Speliotes EK, Butler JL, Palmer CD, Voight BF, Hirschhorn JN ; GIANT Consortium; MIGen Consortium; NASH CRN. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 2010; 52 (3) 904-912
  CrossrefPubMedGoogle Scholar
• 60 Angelico F, Del Ben M, Conti R , et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2005; 90 (3) 1578-1582
  CrossrefPubMedGoogle Scholar
• 61 Farese Jr RV, Zechner R, Newgard CB, Walther TC. The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance. Cell Metab 2012; 15 (5) 570-573
  CrossrefPubMedGoogle Scholar
• 62 Chen W, Chang B, Li L, Chan L. Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease. Hepatology 2010; 52 (3) 1134-1142
  CrossrefPubMedGoogle Scholar
• 63 Basantani MK, Sitnick MT, Cai L , et al. Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome. J Lipid Res 2011; 52 (2) 318-329
  CrossrefPubMedGoogle Scholar
• 64 Kumari M, Schoiswohl G, Chitraju C , et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab 2012; 15 (5) 691-702
  CrossrefPubMedGoogle Scholar
• 65 Huang Y, Cohen JC, Hobbs HH. Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J Biol Chem 2011; 286 (43) 37085-37093
  CrossrefPubMedGoogle Scholar
• 66 Li JZ, Huang Y, Karaman R , et al. Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J Clin Invest 2012; 122 (11) 4130-4144
  CrossrefPubMedGoogle Scholar
• 67 Greenberg AS, Coleman RA, Kraemer FB , et al. The role of lipid droplets in metabolic disease in rodents and humans. J Clin Invest 2011; 121 (6) 2102-2110
  CrossrefPubMedGoogle Scholar
• 68 Browning JD, Cohen JC, Hobbs HH. Patatin-like phospholipase domain-containing 3 and the pathogenesis and progression of pediatric nonalcoholic fatty liver disease. Hepatology 2010; 52 (4) 1189-1192
  CrossrefPubMedGoogle Scholar
• 69 Ratziu V, Cadranel JF, Serfaty L , et al. A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in France. J Hepatol 2012; 57 (2) 376-383
  CrossrefPubMedGoogle Scholar
• 70 Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 2010; 24 (5) 695-708
  CrossrefPubMedGoogle Scholar
• 71 Festi D, Schiumerini R, Marzi L , et al. Review article: the diagnosis of non-alcoholic fatty liver disease — availability and accuracy of non-invasive methods. Aliment Pharmacol Ther 2013; 37 (4) 392-400
  CrossrefPubMedGoogle Scholar
• 72 Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55 (7) 434-438
  PubMedGoogle Scholar
• 73 Mirnezami R, Nicholson J, Darzi A. Preparing for precision medicine. N Engl J Med 2012; 366 (6) 489-491
  CrossrefPubMedGoogle Scholar
• 74 Valenti L, Dongiovanni P, Ginanni Corradini S, Burza MA, Romeo S. PNPLA3 I148M variant and hepatocellular carcinoma: a common genetic variant for a rare disease. Dig Liver Dis 2013; 45 (8) 619-624
  CrossrefPubMedGoogle Scholar
• 75 Sevastianova K, Kotronen A, Gastaldelli A , et al. Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans. Am J Clin Nutr 2011; 94 (1) 104-111
  CrossrefPubMedGoogle Scholar
• 76 Calamita G, Portincasa P. Present and future therapeutic strategies in non-alcoholic fatty liver disease. Expert Opin Ther Targets 2007; 11 (9) 1231-1249
  CrossrefPubMedGoogle Scholar
• 77 Petit JM, Guiu B, Masson D , et al. Specifically PNPLA3-mediated accumulation of liver fat in obese patients with type 2 diabetes. J Clin Endocrinol Metab 2010; 95 (12) E430-E436
  CrossrefPubMedGoogle Scholar
• 78 Goran MI, Walker R, Le KA , et al. Effects of PNPLA3 on liver fat and metabolic profile in Hispanic children and adolescents. Diabetes 2010; 59 (12) 3127-3130
  CrossrefPubMedGoogle Scholar
• 79 Cox AJ, Wing MR, Carr JJ , et al. Association of PNPLA3 SNP rs738409 with liver density in African Americans with type 2 diabetes mellitus. Diabetes Metab 2011; 37 (5) 452-455
  CrossrefPubMedGoogle Scholar
• 80 Li Y, Xing C, Tian Z, Ku HC. Genetic variant I148M in PNPLA3 is associated with the ultrasonography-determined steatosis degree in a Chinese population. BMC Med Genet 2012; 13: 113
  CrossrefPubMedGoogle Scholar
• 81 Viganò M, Valenti L, Lampertico P , et al. Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B. Hepatology 2013;
  PubMedGoogle Scholar
• 82 Corradini SG, Burza MA, Molinaro A, Romeo S. Patatin-like phospholipase domain containing 3 sequence variant and hepatocellular carcinoma. Hepatology 2011; 53 (5) 1776 , author reply 1777
  CrossrefPubMedGoogle Scholar
• 83 Falleti E, Fabris C, Cmet S , et al. PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence. Liver Int 2011; 31 (8) 1137-1143
  CrossrefPubMedGoogle Scholar
• 84 Guyot E, Sutton A, Rufat P , et al. PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis. J Hepatol 2013; 58 (2) 312-318
  CrossrefPubMedGoogle Scholar